Genetic Engineering & Biotechnology News

MAY15 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: http://gen.epubxp.com/i/819033

Contents of this Issue

Navigation

Page 31 of 37

30 | MAY 15, 2017 | GENengnews.com | Genetic Engineering & Biotechnology News Antibody Drug Advantages Antibodies offer several favorable character- istics such as high specificity, minimal off-target effects and good safety profiles. By triggering several immune effector mechanisms, antibodies can effectively neutralize pathogens, inactivate target antigens or destroy malignant cells. In ad- dition, because antibody manufacturing follows a similar process regardless of the intended drug target, costs and risks of development are lower than with new small molecule drugs. Given these advantages, it is perhaps not surprising that anti- bodies have proven enormously successful both medically and commercially, transforming treat- ment and producing more than 50% of all drug sales, reaching a total of $80B globally in revenue in 2015. With over 500 new antibodies in the pipeline, the trend is expected to continue and an- tibody drug sales are projected to nearly double by 2020, reaching $150B globally. OmniAb®, an Outstanding Antibody Discovery Platform Although a few therapeutic antibodies on the market were identified using in vitro techniques, the vast majority of approved monoclonal anti- bodies were generated using mice. Immunization of rodents leverages complex immune processes, notably antibody affinity maturation and rep- ertoire selection, that cannot be recreated com- pletely in vitro. However, to avoid triggering a harmful immune reaction in human patients, non-human immunoglobulin (Ig) sequences must be eliminated from rodent antibodies. This can be accomplished through humanization of antibodies produced from endogenous rodent Ig genes. However, it is less time consuming and risky to simply immunize transgenic animals bearing human immunoglobulin sequences. As part of its mission to provide innovative tech- nologies to enhance drug discovery, Ligand Phar- maceuticals offers an antibody platform called OmniAb. Since its introduction five years ago, the OmniAb platform has proved a highly suc- cessful antibody discovery engine, with over 300 successfully completed antibody discovery proj- ects to date, including four IND submissions and testing in human patients. The OmniAb platform encompasses three animal models, OmniRat ® , OmniFlic ® , and OmniMouse ® . All produce diverse, high titer antigen-specific antibodies and offer several im- portant advantages over competing humanized rodent platforms: • Freedom to operate worldwide and all indications • Complementary humanized rat and mouse models for broader epitope coverage and greater antibody diversity • Development of bi-specific antibodies with a common light chain • Potential outsourcing of animal care and antibody generation to Ligand-approved animal service providers and contract research organizations (CROs) A Unique Patented Technology Various transgenic mice expressing human antibodies have been developed using embryonic stem (ES) cell technology. The ES methods devel- oped in mice proved unworkable in rat, initially limiting commercial antibody discovery to a few Corporate Capabilities OmniAb Ligand 3911 Sorrento Valley Blvd. Suite 110 San Diego, CA 92121 Website www.omniab.com email omniab@ligand.com Advertorial

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - MAY15 2017